Stocksigma LogoStocksigma Logo

CRISIL Reaffirms Zydus Lifesciences Top-Tier Credit Ratings with Stable Outlook

CRISIL Ratings reaffirmed Zydus Lifesciences Limited's long-term rating at CRISIL AAA/Stable for Rs. 4,724 crore bank facilities and Rs

CRISIL Reaffirms Zydus Lifesciences Top-Tier Credit Ratings with Stable Outlook

Zydus Lifesciences Ltd 路 Others (Uncategorized) 路 11 Sept 2026, 8:05 pm

CRISIL Reaffirms Zydus Lifesciences Top-Tier Credit Ratings with Stable Outlook CRISIL Ratings reaffirmed Zydus Lifesciences Limited's long-term rating at CRISIL AAA/Stable for Rs. 4,724 crore bank facilities and Rs. 125 crore NCDs, alongside CRISIL A1+ for short-term facilities and Rs. 200 crore commercial paper on 10th Sep'26. Ratings reflect the company鈥檚 dominant domestic formulations standing, expanding international presence, and robust financial profile. Despite adjusted debt rising to Rs. 12,515 crore in FY26 due to acquisitions, net debt to Ebitda remained strong at 0.60x, with Rs. 7,465 crore in cash and equivalents ensuring superior liquidity.

Original exchange filing (PDF)

More announcements from Zydus Lifesciences Ltd

All Zydus Lifesciences Ltd announcements